US2024034805A1PendingUtilityA1
Anti-Jagged Antibodies and Methods of Use

Assignee: GENENTECH INCPriority: Aug 13, 2012Filed: May 22, 2023Published: Feb 1, 2024
Est. expiryAug 13, 2032(~6 yrs left)· nominal 20-yr term from priority
C07K 16/28C07K 16/18C07K 16/2896C07K 16/30A61K 47/6849A61K 39/3955C07K 16/24A61K 2039/505A61P 35/00A61K 39/395C07K 2317/21C07K 2317/73C07K 2317/76C07K 2317/92A61P 35/02A61P 43/00C07K 16/22C07K 2317/24C07K 2317/56C07K 2317/565C07K 2317/567
PatentIndex Score
Cited by
References
Claims
Abstract

The invention provides anti-Jagged antibodies and methods of using the same.
Claims

exact text as granted — not AI-modified
1 .- 43 . (canceled) 
     
     
         44 . Isolated nucleic acid encoding an antibody that binds to Jagged1, the antibody comprising:
 (a)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:81; 
 (ii) HVR-H2 comprising an amino acid sequence of SEQ ID NO:84; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:87; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:110; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:111; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:114; 
   (b)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:81; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:82; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:85; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:110; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:111; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:112; 
   (c)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:81; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:82; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:86; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:110; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:111; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:113; 
 or 
   (d)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:81; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:83; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:85; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:110; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:111; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:112. 
   
     
     
         45 . A host cell comprising the nucleic acid of  claim 44 . 
     
     
         46 . Isolated nucleic acid encoding an antibody that binds to Jagged2, the antibody comprising:
 (a)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:88; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:94; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:122; 
   (b)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:90; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:117: 
   (c)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:91; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:118: 
   (d)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:90; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:119: 
   (e)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:92; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:120; 
 or 
   (f)
 (i) an HVR-H1 comprising the amino acid sequence of SEQ ID NO:88; 
 (ii) an HVR-H2 comprising the amino acid sequence of SEQ ID NO:89; 
 (iii) an HVR-H3 comprising the amino acid sequence of SEQ ID NO:93; 
 (iv) an HVR-L1 comprising the amino acid sequence of SEQ ID NO:115; 
 (v) an HVR-L2 comprising the amino acid sequence of SEQ ID NO:116; and 
 (vi) an HVR-L3 comprising the amino acid sequence of SEQ ID NO:121. 
   
     
     
         47 . A host cell comprising the nucleic acid of  claim 46 . 
     
     
         48 . A method of producing an antibody comprising culturing the host cell of  claim 45  so that the antibody is produced. 
     
     
         49 .- 58 . (canceled) 
     
     
         59 . A method of producing an antibody comprising culturing the host cell of  claim 47  so that the antibody is produced. 
     
     
         60 . Isolated nucleic acid encoding an antibody that binds to Jagged1/2, the antibody comprising:
 (a)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:95; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:96; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:99; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:123; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:124; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:127; 
   (b) (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:95;
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:96; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:97; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:123; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:124; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:125; 
   (c)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:95; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:96; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:98; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:123; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:124; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:126; 
   (d)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:105; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:109; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:134; or 
   (e)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:100; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:107; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:130; 
   (f)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:100; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:108; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:131; 
   (g)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:101; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:107; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:132; 
   (h)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:102; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:107; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:133; 
   (i)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:103; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:107; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:132; 
 or 
   (j)
 (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:104; 
 (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:106; 
 (iii) HVR-H3 comprising an amino acid sequence of SEQ ID NO:107; 
 (iv) HVR-L1 comprising the amino acid sequence of SEQ ID NO:128; 
 (v) HVR-L2 comprising the amino acid sequence of SEQ ID NO:129; and 
 (vi) HVR-L3 comprising an amino acid sequence of SEQ ID NO:132. 
   
     
     
         61 . A host cell comprising the nucleic acid of  claim 60 . 
     
     
         62 . A method of producing an antibody comprising culturing the host cell of  claim 61  so that the antibody is produced. 
     
     
         63 . The nucleic acid of  claim 44 , wherein the antibody is a monoclonal antibody. 
     
     
         64 . The nucleic acid of  claim 44 , wherein the antibody is a humanized or chimeric antibody. 
     
     
         65 . The nucleic acid of  claim 46 , wherein the antibody is a monoclonal antibody. 
     
     
         66 . The nucleic acid of  claim 46 , wherein the antibody is a humanized or chimeric antibody. 
     
     
         67 . The nucleic acid of  claim 60 , wherein the antibody is a monoclonal antibody. 
     
     
         68 . The nucleic acid of  claim 60 , wherein the antibody is a humanized or chimeric antibody. 
     
     
         69 . The nucleic acid of  claim 44 , wherein the antibody comprises:
 (a)
 (i) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:10; 
 (ii) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:19; or 
 (iii) a VH sequence as in (i) and a VL sequence as in (ii); 
   (b)
 (i) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:11; 
 (ii) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:20; or 
 (iii) a VH sequence as in (i) and a VL sequence as in (ii); 
   (c)
 (i) a VH sequence of SEQ ID NO:10; 
 (ii) a VL sequence of SEQ ID NO:19; or 
 (iii) a VH sequence of SEQ ID NO:10 and a VL sequence of SEQ ID NO:19; 
 or 
   (d)
 (i) a VH sequence of SEQ ID NO:11; 
 (ii) a VL sequence of SEQ ID NO:20; or 
 (iii) a VH sequence of SEQ ID NO:11 and a VL sequence of SEQ ID NO:20. 
   
     
     
         70 . The nucleic acid of  claim 46 , wherein the antibody comprises:
 (a)
 (i) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:15; 
 (ii) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:24; or 
 (iii) a VH sequence as in (a) and a VL sequence as in (b); or 
   (b)
 (i) a VH sequence of SEQ ID NO:15; 
 (ii) a VL sequence of SEQ ID NO:24; or 
 (iii) a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:24. 
   
     
     
         71 . The nucleic acid of  claim 60 , wherein the antibody comprises:
 (a)
 (i) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:17; 
 (ii) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:26; or 
 (iii) a VH sequence as in (i) and a VL sequence as in (ii); 
   (b)
 (i) a VH sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:30; 
 (ii) a VL sequence having at least 95% sequence identity to the amino acid sequence of SEQ ID NO:28; or 
 (iii) a VH sequence as in (i) and a VL sequence as in (ii). 
   (c)
 (i) a VH sequence of SEQ ID NO:17; 
 (ii) a VL sequence of SEQ ID NO:26; or 
 (iii) a VH sequence of SEQ ID NO:17 and a VL sequence of SEQ ID NO:26; or 
   (d)
 (i) a VH sequence of SEQ ID NO:30; 
 (ii) a VL sequence of SEQ ID NO:28; or 
 (iii) a VH sequence of SEQ ID NO:30 and a VL sequence of SEQ ID NO:28. 
   
     
     
         72 . The nucleic acid of  claim 44 , wherein the antibody is a full length IgG1 antibody. 
     
     
         73 . The nucleic acid of  claim 46 , wherein the antibody is a full length IgG1 antibody. 
     
     
         74 . The nucleic acid of  claim 60 , wherein the antibody is a full length IgG1 antibody.
Join the waitlist — get patent alerts

Track US2024034805A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.